CalciMedica, Inc. (CALC) is a publicly traded company in the Healthcare sector, operating within the Biotechnology industry. The company is headquartered in La Jolla, CA, United States. The current CEO is A. Rachel Leheny.
CALC has IPO date of 2023-06-14, 14 full-time employees, listed on the NASDAQ Capital Marke, a market capitalization of $10M.
CalciMedica, Inc., a clinical-stage biotechnology company, focuses on developing therapies for life-threatening inflammatory diseases with unmet needs. Its proprietary technology targets the inhibition of calcium release-activated (CRAC) channels designs to modulate the immune response and protect against tissue cell injury in life-threatening inflammatory diseases. Its lead product candidate is Auxora, a proprietary intravenous-formulated CRAC channel inhibitor for the treatment of acute pancreatitis, asparaginase-associated acute pancreatitis, and acute kidney injury. The company is based in La Jolla, California.
